Bellosta et al[@bib1] recently demonstrated a significantly higher incidence of acute limb ischemia (ALI) in COVID-19 patients. In addition, an increased failure rate after revascularization occurred. The colleagues must be complemented for their clinical and scientific commitments. The increased thromboembolic complications in COVID-19 patients have been reported even in those receiving anticoagulant therapy and in nonatherosclerotic patients.[@bib1], [@bib2], [@bib3] More than 27,000 COVID-19 cases were registered in our region (Emilia-Romagna). Our unit represents the unique vascular surgery service in the province of Modena. As a tertiary COVID center, we did not observe ALI in such patients. It must be taken into account that Bellosta et al[@bib1] provide care in an Italian region with a higher incidence of COVID-19 (Lombardia). However, this difference of incidence in northern Italy remains unclear. We observed two COVID-19 patients with concomitant pulmonary embolism (PE) and aortic floating thrombus (AFT; [Fig](#fig1){ref-type="fig"} ). They were asymptomatic for peripheral embolism and without a source for the PE. Because of the PE, anticoagulant therapy and low-dose antiplatelet therapy were initiated. A significant reduction of the AFT was observed with resolution of the PE in both patients. The AFT is a rare but serious clinical condition able to cause dramatic peripheral embolism.[@bib4] Aortic stent implantation, abnormal coagulation function, and aortic diseases were reported as predictors of AFT.[@bib4] Medical therapy was proposed as the treatment of choice in asymptomatic AFT patients.[@bib4] Following the plethora of procoagulant modifications described in COVID-19 patients and the above-mentioned trends to intrastent thrombus relapse, we preferred to avoid invasive procedures.[@bib4] ^,^ [@bib5] FigA COVID-19 patient (pneumonia, *green arrows*) with concomitant pulmonary embolism (PE; **A**) and aortic floating thrombus (AFT; **C**) in the aortic arch and in the left subclavian artery. After 8 days of anticoagulant and antiplatelet therapy, the PE was resolved **(B)**, and the AFT was reduced **(D)**.

Indeed, the AFT may be a more common source of ALI in COVID-19.

The preoperative workup reported by Bellosta et al[@bib1] did not include thoracic computed tomography (CT) angiography. COVID-19 patients are usually diagnosed by means of CT scans, and our observations were possible thanks to the use of contrast medium.

Finally, thoracoabdominal CT angiography should be considered a routine evaluation in COVID-19 patients presenting with embolic complications.

Clearly, further investigations are required: the thrombotic mechanism; the type, dose, and duration of the anticoagulant therapy; and the indications for and timing of surgical management of thrombus and emboli.[@bib1], [@bib2], [@bib3] ^,^ [@bib5]
